Ram Dayal

Dr. Ram Dayal

Devine International Group of Institution, Gwalior, India
+3
orcid
Professor cum Director at Sunder Deep Pharmacy College, Ghaz...

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2018 in Asian Journal of Pharmaceutical and Clinical Research
Verified
Journal Article
Open access
PDF file
HSHarjeet Singh
Harjeet Singh
Ram DayalRam Dayal
Ram Dayal
GGGirendra Gautam
Girendra Gautam
Objective: The aim of this study was to formulate and optimize solid lipid nanoparticles (SLNs) for the enhancement of solubility and bioavailability of the poorly aqueous soluble drug rosuvastatin calcium.Methods: SLNs were prepared by slight modification of solvent emulsification-diffusion technique and analyzed for particle size, zeta potential, drug entrapment efficiency, in vitro drug release, stability, and pharmacokinetic studies. Rosuvastatin calcium SLNs were formulated using stearic acid as main lipid, poloxamer 407 as surfactant, and Tween 80 as cosurfactant.Results: All parameters were found to be in an acceptable range. Optimized formulation OR2 SLNs have shown mean particle size 115.49±2.97 nm with polydispersity index value of 0.456, zeta potential - 18.40 mV, 60.34% drug loading, and 97.16% drug entrapment efficiency. In vitro drug release was found to be 88.70±3.59% after 12 h with sustained release and was fitted with Higuchi model with a very high correlation coefficient (R2=0.9905). Transmission electron microscopy confirms that the SLNs of selected optimized formulation are circular in shape. Differential scanning calorimetry and X-ray diffraction confirm the formation of amorphous product. 1H nuclear magnetic resonance studies confirm the intermolecular hydrogen bonding between drug and lipid. Pharmacokinetic studies showed an optimized formulation OR2 SLNs enhanced bioavailability with 4.44-fold as compare to plain drug suspension. Optimized formulation OR2 SLNs have shown good stability at 25±2°C and 60±5°C relative humidity for 180 days.Conclusion: Thus, the current study can be useful for the successful development of optimized SLNs and able to enhance the bioavailability of poorly soluble drug rosuvastatin calcium.

1 February 2018 in Asian Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
HSHarjeet Singh
Harjeet Singh
Ram DayalRam Dayal
Ram Dayal
Girendra Kumar GautamGirendra Kumar Gautam
Girendra Kumar Gautam

25 September 2024 in International Journal of Drug Delivery Technology
Verified
Journal Article
Open access
RCRishika . Chauhan
Rishika . Chauhan
Balwan SinghBalwan Singh
Balwan Singh
Ram DayalRam Dayal
Ram Dayal
AMAnuj Malik . Malik
Anuj Malik . Malik
Numerous chemopreventive drugs like aloin and curcumin have demonstrated potential effects in cancer treatment; however, their efficacy is limited by low bioavailability. Thus, the primary goal of this research was to formulate a unique method by using the herbal drugs synergistically and improve the bioavailability of these anticancer drugs here, using the nanoprecipitation method for two well-active constituents of known natural herbal compounds. Aloin (AL)-curcumin (CUR) were co-loaded into polymeric nanoparticles made of poly (D, L-lactide-co-glycolide) and surfactant-polyvinyl alcohol, with the experiment’s response being evaluated using Stat-Ease software. To create dual-loaded nanoparticles containing aloin and curcumin, using different ratios sand optimizing the best formulation. (60:120). For aloin curcumin, optimize the better formulation with controlled release formulation having less than 100 nm size of particle and drug entrapment was 86.09% while for (60:60) of aloin -curcumin having 99.1 nm particle size of drug and encapsulation efficiency was 72.05%.

1 February 2021 in Coronaviruses
Verified
Journal Article
Closed access
PDF file
SGSurya Goel
Surya Goel
Ram DayalRam Dayal
Ram Dayal
Background: The widespread of novel coronavirus is a global concern. With each passing day, the novel coronavirus is making its new borders. Research has revealed that the virus produced in bats and was transmitted to humans firstly in Wuhan, Hubei province of China in December 2019. The contagion has been significantly acting as a vulnerable threat to the copious world. Objective: The purpose of this review is to provide the valuable and detailed information about the historical background, origin, classification, morphology, transmission pattern, symptoms, treatment parameters, number of cases as well as the preventive measures of the corona-virus disease 2019 (COVID- 19). Methods: The disease is transmitted to people by inhalation or close contact of infected droplets. To split the sequential chain of this contagious disease, we need to know about its symptoms, ways of transmission, preventive measures and safety guidelines. Results: The widespread of COVID-19 is a global concern. The morbidity rate due to COVID-19 is increasing regularly. As for now, there is no specific cure, vaccine and treatment; the lives can be saved only by following the preventive measures and safety guidelines. Conclusion: Several clinical trials are in progress for the development of a suitable vaccine to combat this disease. This review shall be helpful in providing detailed information regarding the novel coronavirus so that the sequences of such infection can be reduced.

1 January 2024 in Journal of Applied Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
PKPraveen Kumar
Praveen Kumar
HSHimanshu Sachdeva
Himanshu Sachdeva
SKSunishtha Kalra
Sunishtha Kalra
Balwan SinghBalwan Singh
Balwan Singh
Ram DayalRam Dayal
Ram Dayal
GSGovind Singh
Govind Singh
Oxalis corniculata and Ficus religiosa mitigates rotenone-induced Parkinson’s disease in Swiss Albino mice: Mechanistic insights and therapeutic potential

1 December 2023
Verified
Book Chapter
Open access
Ram DayalRam Dayal
Ram Dayal
BSBalwan Singh
Balwan Singh
KNK Nagarajan
K Nagarajan
VCVivekanand Kisan Chatap
Vivekanand Kisan Chatap
Biopharmaceutical Research & Development (R&D) aims at finding new modalities to diagnose, prevent, and treat human diseases. Prototypes of innovative approaches are tested in biological systems of increasing size, complexity, and relevance. Active Drug Ingredient (API) is a substance used to diagnose, treat, reduce, cure, or prevent disease. Medicines can be solid (pill, capsule), semi-solid (ointment, cream), liquid, suspension, emulsion, etc., for internal or local use. It is given in some drug or drug forms such as Pharmaceutical products can be thought of as pharmaceutical products that release and deliver drugs to the site of action, cause desired medical results, and are also specifically designed to meet the patient's needs such as palatability, convenience, and safety. Health authorities around the world play a key role in this process. During the clinical test phase, together with the biopharmaceutical companies, they surveil and ensure the scientifically sound and safe conduct of clinical trials. In a second step, health authorities review the entire data set that has been generated during both the exploratory and the confirmatory phases. If, based on these data, they come to conclude that the benefits conferred to the patients outweigh the risks, authorization to market the drug in the respective country is conferred. In order to get reimbursed, approved new drugs need to undergo an economic review process. There the decision is made if the new drug confers enough clinical benefits to justify its price. The drug approval process and the economic evaluation/reimbursement process are two distinct processes carried out by different institutions. Although R&D leverages a number of academic disciplines like epidemiology, genetics, biology, chemistry, bioinformatics, pharmacology, toxicology, pharmacy, and medicine, it is not primarily an academic discipline and cannot be studied in one program at a university. It is difficult to find coherent overarching information on concepts generally applicable to the industry beyond individual company processes. Thus, this book chapter attempts to bridge this gap and provide an overview and concepts and reliable details which apply across the industry and are valuable for everyone working in or with the biopharmaceutical industry.